Compare Expeditors International of Wshngtn Inc (EXPD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Repligen Corporation Common Stock — how do they compare? Expeditors International of Wshngtn Inc trades at $195.87 (market cap $25.37B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 2.3× Repligen Corporation Common Stock's market cap, and Expeditors International of Wshngtn Inc pays a 0.83% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 44 Days and Repligen Corporation Common Stock for 0 Days on average.
| EXPD | RGEN | |
|---|---|---|
Market Cap | $25.37B | $11.14B |
Volume | 1,236,812 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $196.38 | $194.57 |
52-Week Low | $117.35 | $102.87 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $24.90B | $11.02B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $196.38, up 1.54% today, with a bullish technical signal from moving averages and strong profitability metrics including a 42.6% ROE. Recent quarters show consistent earnings beats, and cash flow improved to a positive $166 million in 2025. News highlights efficiency initiatives and AI's impact on freight markets, supporting positive momentum.
The stock's outlook is mixed; fundamentals are solid with revenue growth to $12.0B projected for 2026, but valuation is elevated at a P/E of 28.4, and analyst consensus is cautious with a $179.43 price target below current levels. Risks include reliance on freight demand cycles and competitive pressures in logistics.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
